La cadena de opciones muestra datos clave de las opciones de acciones de Vast Renewables Ltd a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Vast Renewables Ltd..

Vast Renewables Ltd (OTC:VSTE) Bolsa, Cadena de Opciones

Urban Outfitters

ATCH

BTOG

DGLY

KDLY

LTRY

LUMN

MANU

NINE

NVTS

SEDG

SNOW

UPXI

URBN

VSTE

VTAK

WHLR

Longevity Health Holdings, Inc. - Common Stock

XAGE

Urban Outfitters sube tras superar expectativas de beneficios; otras acciones como Navitas y Snowflake también destacan en el premercado.

Acciones de Urban Outfitters (URBN) se disparan un 18%; Aquí están 20 acciones que se mueven en el premercado

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

ACLS

AMKR

BHAT

BNAI

FLNC

GNPX

HLIT

LIXT

LSCC

NLSP

OCEA

PRLD

SGRY

SLQT

SLXN

TANH

Lattice Semiconductor sorprende con un alza del 14,7% en el premercado. Descubre qué otras acciones están en movimiento.

Acciones de Lattice Semiconductor (LSCC) suben un 15%; 20 acciones que se mueven en el premercado

Earnings

APDN

AUID

CERO

COMM

CRVS

EFSH

FSBW

NIVF

NUKK

PRTG

PRZO

PTPI

RZLV

SHLT

SSBK

TNXP

Acciones de Corvus suben un 22,5% pre-market tras anunciar datos de Soquelitinib. Descubre más ganadores y perdedores.

Acciones de Corvus Pharmaceuticals (CRVS) suben alrededor del 22%; 20 acciones que se mueven en premercado

Vast Renewables Ltd

Vast Renewables Ltd Warrants (01/07/2028)

The U.S. Food and Drug Administration (FDA) sent a &#8220;refusal to file&#8221; letter to Axsome Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXSM#NASDAQ">AXSM</a>) on Monday regarding its AXS-14 (esreboxetine) treatment <a href="https://www.benzinga.com/general/health-care" target="_blank" rel="noreferrer noopener">of fibromyalgia</a>.
The FDA states that upon preliminary review, the New Drug Application (NDA) was not sufficiently complete to <a href="https://www.benzinga.com/pressreleases/25/06/g45832920/axsome-therapeutics-provides-update-on-the-new-drug-application-nda-for-axs-14-for-the-management-" target="_blank" rel="noreferrer noopener">permit a substantive review</a>.
Fibromyalgia is a chronic disorder characterized by widespread pain, fatigue, disturbed sleep, depression, and cognitive impairment.
Approximately 17 million Americans, 90% of whom are women, are estimated to suffer from fibromyalgia.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/04/44587826/axsomes-solriamfetol-fails-primary-goal-in-depression-study-but-shows-improvements-in-associated-sleep-disorder" rel="noreferrer noopener">Axsome&#8217;s Solriamfetol Fails Primary Goal In Depression Study But Shows Improvements In Associated Sleep Disorder</a>
Specifically, the FDA does not consider the second of the two placebo-controlled trials in the submission adequate and well-controlled because its primary endpoint was at 8 weeks, and it used a flexible-dose paradigm.
The FDA indicated that the first of the two placebo-controlled trials in the submission, which utilized a 12-week endpoint and a fixed-dose paradigm, is adequate and well-controlled.
The FDA did not raise any questions relating to the positive results of the studies, both of which met their primary endpoints.
To address the FDA&#8217;s feedback, Axsome will conduct an additional controlled trial. As requested by the FDA, this trial will use a fixed-dose paradigm and a 12-week primary endpoint. Axsome anticipates initiating this trial in the fourth quarter of 2025.
Axsome CEO Herriot Tabuteau said the company is &#8220;well positioned to initiate a new controlled trial that will incorporate the FDA&#8217;s feedback by the end of 2025.&#8221;
While the RTF is disappointing, William Blair had ascribed only $3.38 for the AXS-14 fibromyalgia program to total $199.98 sum-of-the-parts fair value in the model.
With the requirement for an additional study, analyst Myles Minter has delayed the launch of AXS-14 in the model to the second half of 2028 and now ascribes $1.89 for the program to the fair value.
Investor focus remains on the Alzheimer's disease agitation (AD-A), which is on track for the third quarter of 2025.
After talking with the company's management, William Blair said they believe the recent Refusal to File (RTF) is limited to the Division of Anesthesiology, Addiction Medicine, and Pain Medicine and the fibromyalgia program.
It should not impact the separate submission for AXS-05 in Alzheimer's disease agitation, which will go through the Psychiatry division in Q3 2025. 
The firm added that getting a PDUFA date for this application, supported by the ADVANCE and ACCORD studies, and possibly receiving priority review due to its breakthrough therapy status, would be a key milestone and help reduce concerns about FDA-related delays caused by its internal restructuring.
Price Action: AXSM stock is down 0.60% at $111.24 at the last check on Monday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/movers/25/02/43790716/axsomes-axs-05-in-alzheimers-agitation-could-be-billion-dollar-opportunity-says-analyst" target="_blank" rel="noreferrer noopener">Axsome&#8217;s AXS-05 In Alzheimer&#8217;s Agitation Could Be Billion Dollar Opportunity, Says Analyst</a></li>
</ul>
Image: Shutterstock

Analyst Color

Biotech

Health Care

Analyst Ratings

General

AXSM

FDA Pushes Pause On Axsome Fibromyalgia Drug, New Trial Required

Morgan Stanley analyst John Glass downgrades McDonald's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCD#NYSE">MCD</a>) from Overweight to Equal-Weight and lowers the price target from $329 to $324.

Downgrades

Price Target

Morgan Stanley Downgrades McDonald's to Equal-Weight, Lowers Price Target to $324

Academy Sports and Outdoors, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASO#NASDAQ">ASO</a>) will release its first-quarter financial results before the <a href="https://www.benzinga.com/quote/ASO">opening bell on Tuesday, June 10.</a>
Analysts expect the Katy, Texas-based company to report quarterly earnings at 89 cents per share, down from $1.08 per share in the year-ago period. Academy Sports and Outdoors projects quarterly revenue of $1.37 billion, compared to $1.36 billion a year earlier, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
On June 6, Academy Sports and Outdoors declared a quarterly cash dividend of 13 cents per share.
Academy Sports and Outdoors shares gained 2% to trade at $44.31 on Monday.
Benzinga readers can access the latest analyst ratings on the <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">Analyst Stock Ratings</a> page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.
Let's have a look at how Benzinga's most-accurate <a href="https://www.benzinga.com/quote/aso/analyst-ratings">analysts have rated the company</a> in the recent period.
<ul class="wp-block-list">
<li>Citigroup analyst Paul Lejuez maintained a Buy rating and cut the price target from $60 to $55 on June 4, 2025. This analyst has an accuracy rate of 64%.</li>
<li>UBS analyst Michael Lasser maintained a Neutral rating and slashed the price target from $54 to $48 on June 4, 2025. This analyst has an accuracy rate of 79%.</li>
<li>Wells Fargo analyst Ike Boruchow maintained an Equal-Weight rating and raised the price target from $38 to $43 on May 14, 2025. This analyst has an accuracy rate of 71%.</li>
<li>Evercore ISI Group analyst Greg Melich maintained an In-Line rating and cut the price target from $54 to $53 on April 1, 2025. This analyst has an accuracy rate of 81%.</li>
<li>JP Morgan analyst Christopher Horvers maintained a Neutral rating and raised the price target from $52 to $54 on March 21, 2025. This analyst has an accuracy rate of 71%</li>
</ul>
Considering buying ASO stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><a href="https://www.benzinga.com/quote/ASO/analyst-ratings"><img loading="lazy" decoding="async" width="1024" height="407" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/09123435/image-121-1024x407.png" alt="" class="wp-image-943539" style="width:577px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/09123435/image-121-1024x407.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/09123435/image-121-300x119.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/09123435/image-121-768x305.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/09123435/image-121.png 1501w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/25/06/45835438/top-3-financial-stocks-that-may-collapse-in-june">Top 3 Financial Stocks That May Collapse In June</a> </li>
</ul>
Photo via Shutterstock

Top Wall Street Forecasters Revamp Academy Sports and Outdoors Expectations Ahead Of Q1 Earnings

Morgan Stanley analyst Erin Wright initiates coverage on Molina Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOH#NYSE">MOH</a>) with a Overweight rating and announces Price Target of $364.

Initiation

Morgan Stanley Initiates Coverage On Molina Healthcare with Overweight Rating, Announces Price Target of $364

Morgan Stanley analyst Ricky Goldwasser initiates coverage on Centene (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNC#NYSE">CNC</a>) with a Overweight rating and announces Price Target of $70.

Morgan Stanley Initiates Coverage On Centene with Overweight Rating, Announces Price Target of $70

WIIM

NCPL

Netcapital shares are trading higher following the announcement that its portfolio company, Zelgor, has completed the acquisition of Mixie.

Morgan Stanley analyst Alexandra Steiger downgrades Lululemon Athletica (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LULU#NASDAQ">LULU</a>) from Overweight to Equal-Weight and lowers the price target from $346 to $280.

LULU

Morgan Stanley Downgrades Lululemon Athletica to Equal-Weight, Lowers Price Target to $280

SCHW

The Schwab Trading Activity Index Decreased To 39.68 In May, Down From Its Score Of 41.18 In April

Morgan Stanley analyst Dara Mohsenian reiterates Coca-Cola (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KO#NYSE">KO</a>) with a Overweight and maintains $81 price target.

Reiteration

Morgan Stanley Reiterates Overweight on Coca-Cola, Maintains $81 Price Target

Real estate investor Grant Cardone has navigated multiple economic downturns and can spot trends before most investors notice. He's been highlighting the growing trend of <a href="https://www.tiktok.com/@grantcardone/video/7512161619372166430?lang=en">renting over owning property</a> and explained some of the factors that have led to this change.
"Many people don't want to commit to 30 years. They're on the move," Cardone said.
Cardone mentioned housing prices, shortcomings of the Biden administration, and other details when painting the picture of America becoming a renter nation.
Don't Miss:
<ul class="wp-block-list">
<li>Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing — <a href="https://www.benzinga.com/money/boxabl-scaling-fast-from-spacex-orders-to-600-homes-built-this-60k-foldable-home-may-be-the-future-of-housing">this is your last chance to become an investor for $0.80 per share.</a></li>
<li>Maximize saving for your retirement and cut down on taxes: <a href="https://www.benzinga.com/money/wideradvisor-retirement-planning">Schedule your free call with a financial advisor to start your financial journey – no cost, no obligation</a>.</li>
</ul>
<h2 class="wp-block-heading">A Rolling Recession</h2>
Cardone believes we were in a recession during the Biden administration that wasn&#8217;t properly covered because the definition of a recession was changed. He stated that the U.S. experienced multiple back-to-back quarters of declining GDP, and job numbers only looked decent because 40%-45% of all added jobs were government jobs during the Biden administration.
Cardone mentioned this context since people are more likely to rent than buy during recessions. Mortgages become less accessible during recessions, and people don't have the money to keep up with living costs and save up for a down payment.
He also stated that some people are waiting for housing prices to go down. That's a common strategy during economic contractions, as people hope to buy at a lower price in a few months. Some potential home buyers have no problem with waiting for more affordable prices, and that has resulted in higher demand for the rental market.
Trending: Invest where it hurts — and help millions heal:<a href="https://www.benzinga.com/money/a-cure-for-osteoarthritis-powered-by-everyday-investors-cytonics-is-looking-to-beat-big-pharma-and-disrupt-a-390-billion-market"> Invest in Cytonics and help disrupt a $390B Big Pharma stronghold</a>.
<h2 class="wp-block-heading">More People Are Living Mobile Lifestyles</h2>
Cardone also mentioned that people are being more mobile instead of sticking to one place. This lifestyle makes it easier for people to get up and move to another city. Cardone is a fan of moving every once in a while. He moved from Louisiana to San Diego before moving to Los Angeles and finally Miami, where he currently resides.&nbsp;
Cardone believes you should relocate if you get too comfortable and seem to know everyone in the area. It seems like more people are following up on that advice by renting instead of buying.&nbsp;
Cardone specifically mentioned California and said that less than 16% of Californians own a home. He said that many of them cannot afford it due to high housing costs and the difficulty of qualifying for a mortgage. Getting a mortgage becomes even more difficult when houses are valued at millions of dollars.
See Also: Wall Street's Missing This AI Surgical Tech — You Don't Have To.<a href="https://www.benzinga.com/money/this-ai-imaging-technology-has-been-used-in-more-than-500-surgeries-now-you-can-be-part-of-the-ai-imaging-revolution"> Invest from $350.</a>
<h2 class="wp-block-heading">Housing Is Expensive</h2>
Although you're not building equity when you pay rent, housing isn't free either. Even after paying off the mortgage, you still have to contend with property taxes, repairs, and other homeownership costs. Cardone is on record saying that a primary residence is not a good investment.
Investors might generate higher returns if they put their money into the stock market instead of putting a down payment toward a primary residence. While it's advantageous to have a paid-off mortgage when you retire, your funds might grow faster if you put them to work in better investments.
The debate on buying vs. renting from an investment standpoint mainly applies to people who can afford housing. Cardone mentions that the Biden administration increased the country's debt by $8.4 trillion, and additional increases to the federal debt will make housing and all resources less affordable. Any additional debt causes the purchasing power of the U.S. dollar to decrease.
Read Next: <a href="https://www.benzinga.com/money/gbr-savings-by-age">If You're Age 35, 50, or 60: Here&#8217;s How Much You Should Have Saved Vs. Invested By Now</a>
Image: Shutterstock

Personal Finance

Grant Cardone Explains Why We Are Becoming A Renter Nation: 'Many People Don't Want To Commit To 30 Years. They're On The Move.'

NRG Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NRG#NYSE">NRG</a>) has outperformed the market over the past 5 years by 21.46% on an annualized basis producing an average annual return of 36.0%. Currently, NRG Energy has a market capitalization of $30.67 billion. 
Buying $100 In NRG: If an investor had bought $100 of NRG stock 5 years ago, it would be worth $464.05 today based on a price of $156.85 for NRG at the time of writing.
<h3>NRG Energy's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1749486612_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much $100 Invested In NRG Energy 5 Years Ago Would Be Worth Today

Anthony Pompliano, founder of Professional Capital Management, said he sees stablecoins as one <a href="https://www.benzinga.com/money/bitcoin-price-prediction">key driver for the growth </a>of Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>).
What Happened: Speaking in an <a href="https://www.youtube.com/watch?v=pZ1hlWlYBTk">interview</a> with CNBC on June 9, he pointed to companies like Gemini and Robinhood (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOOD#NASDAQ">HOOD</a>) as examples of platforms adapting their business models to serve both crypto-native and mainstream users.
Retail investors, he noted, now account for roughly 36%–38% of U.S. equities ownership, and many of them have been shaped by the crypto market's volatility. 
This has instilled a strong "buy the dip" mentality among the new generation of traders.
Bitcoin's Future: Hyper-Bitcoinization
Pompliano distinguished between the roles of stablecoins and Bitcoin: stablecoins are ideal for transactions and spending, while Bitcoin currently serves as a digital savings account. 
Over time, however, he believes Bitcoin could take on both functions, a transformation he describes as "Hyper-Bitcoinization." In this scenario, Bitcoin becomes globally accepted not just as a store of value, but also as a widely used medium of exchange.
While this transition is still years away, he sees it as Bitcoin's "final form."
Stablecoins Gaining Ground
Pompliano also discussed the growing stablecoin ecosystem, noting differences in strategy between issuers like Tether (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">USDT</a>) and Circle (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">USDC</a>). 
He suggested that stablecoins which return yield from underlying assets could become increasingly attractive and mentioned ongoing innovation to bring stablecoins onto Bitcoin's blockchain, signaling a broader expansion of Bitcoin's utility.
Also Read: <a href="https://www.benzinga.com/crypto/cryptocurrency/25/06/45833498/bitcoin-ethereum-xrp-dogecoin-start-the-week-green-ahead-of-us-china-trade-talks">Bitcoin, Ethereum, XRP, Dogecoin Start The Week Green Ahead Of US-China Trade Talks</a>
Why It Matters: Pompliano believes that stablecoin companies like Circle are well-positioned to succeed in public markets due to their compatibility with traditional finance systems. 
However, he cautioned that broader success will depend on business fundamentals, not simply being a crypto firm.
He also touched on the impact of macroeconomic volatility, referencing recent geopolitical moves like fluctuating tariffs. These dynamics, he argued, are increasingly relevant as crypto becomes more integrated with the global financial system.
As this integration deepens, crypto assets, particularly Bitcoin, are likely to become more sensitive to traditional economic and geopolitical trends.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/crypto/cryptocurrency/25/06/45835021/bitcoin-pushes-to-107000-as-pivotal-resistance-level-gets-tested-once-again">Bitcoin Pushes To $107,000 As Pivotal Resistance Level Gets Tested Once Again</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

$USDC

$USDT

HOOD

Anthony Pompliano Says Bitcoin's Endgame Is Hyper-Bitcoinization

Melius Research analyst Rob Wertheimer initiates coverage on Waste Connections (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WCN#NYSE">WCN</a>) with a Buy rating and announces Price Target of $213.

Melius Research Initiates Coverage On Waste Connections with Buy Rating, Announces Price Target of $213

NVIDIA Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) is trading higher on Monday after consolidating last week, but the shares may be <a href="https://www.benzinga.com/etfs/sector-etfs/25/06/45796685/nvidia-beats-microsoft-to-be-the-biggest-of-the-big-here-are-6-etfs-riding-its-trillion-dollar-rebound">about to break out.</a>
Breakouts can have bullish implications. This is why our trading team has made NVIDIA our Stock of the Day.
Stock prices are determined by supply and demand. If there is more supply or shares for sale than demand or shares to buy, the price will trend lower. This happens because sellers are forced to undercut each other to attract buyers.
If there are more shares to be bought than there are to be sold, the price will trend higher. Buyers will be forced to outbid each other to draw sellers into the market, causing a snowball effect that pushes the price up.
Rallies end or pause at resistance levels.
Read Also: <a href="https://www.benzinga.com/markets/equities/25/06/45831332/sp-500-hits-6000-level-following-positive-jobs-data-investor-sentiment-improves-fear-index-remains-in-greed-zone">S&amp;P 500 Hits 6,000 Level Following Positive Jobs Data: Investor Sentiment Improves, Fear Index Remains In &#8216;Greed&#8217; Zone</a>
Resistance is a level or narrow price zone where there is enough, or more than enough supply to fill all of the demand. Buyers can acquire as many shares as they like without increasing prices.
Sometimes, stocks reverse and trend lower after they hit resistance. This occurs when some sellers become concerned that others will be willing to sell their shares for a lower price.
As a result, these concerned sellers lower their prices. Other concerned sellers see this and do the same thing. This forces the shares into a downtrend.
But sometimes, when a stock reaches a resistance level, the buyers overpower the sellers, moving the price higher. When this happens, traders say it is a ‘breakout'.
This is a bullish dynamic that suggests the stock will continue to rally. It shows that the sellers who created the resistance have either finished or canceled their orders.
With this large amount of supply removed from the market, buyers will be once again forced to outbid each other, moving the price higher.
As you can see on the chart, NVIDIA encountered resistance around $122.40. After breaking this resistance, the stock made a big move.
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="522" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/09122353/NVDA-chart-1024x522.png" alt="" class="wp-image-943523" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/09122353/NVDA-chart-1024x522.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/09122353/NVDA-chart-300x153.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/09122353/NVDA-chart-768x392.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/09122353/NVDA-chart.png 1431w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Now, NVIDIA is testing and could break resistance around $141.50. It may be on the verge of another upward move.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/macro-economic-events/25/06/45832125/as-trump-flames-powell-for-holding-back-on-rate-cuts-economists-divided-on-feds-approach">As Trump Flames Powell For Holding Back On Rate Cuts, Economists Divided On Fed&#8217;s Approach</a></li>
</ul>
Photo: Shutterstock

Technicals

Tech

NVDA

Stock Of The Day: NVIDIA Tests New Resistance — Could Another Breakout Be Brewing?

Melius Research analyst Rob Wertheimer initiates coverage on Republic Services (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RSG#NYSE">RSG</a>) with a Hold rating and announces Price Target of $281.

Melius Research Initiates Coverage On Republic Services with Hold Rating, Announces Price Target of $281

The public feud between President Donald Trump and Tesla, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) CEO Elon Musk has eased for now, but the tension has weighed on Tesla's stock. However, Wedbush analyst Dan Ives remains bullish on Tesla ahead of Thursday's <a href="https://www.benzinga.com/markets/asia/25/06/45834491/tesla-china-sales-surge-in-may-as-new-model-y-juniper-exported-for-the-first-time-amid-us-china-trade-war">robotaxi launch in Austin.&nbsp;</a>
What To Know: In a research note published Monday, Ives said that the "timing of this globally watched frenemies situation" is not ideal as it coincides with the robotaxi launch. However, Wedbush still expects Tesla to launch its robotaxi services in 20 to 25 cities over the next year without <a href="https://www.benzinga.com/news/politics/25/06/45832509/cathie-wood-warned-about-trump-musk-clash-long-before-it-exploded-now-says-the-feud-exposes-just-how-dependent-elons-empire-is-on-the-us-government">the Trump feud</a> standing in Tesla's way. 
Read Next: <a href="https://www.benzinga.com/news/space/25/06/45840240/trump-musk-feud-fuels-spacex-rivals-space-stock-countdown?utm_source=article">Trump, Musk Feud Fuels SpaceX Rivals: Space Stock Countdown</a>
In fact, Ives thinks there is potential for Trump and Musk to mend their relationship behind the scenes, as both have mutual interests: Trump wants Musk's support for the Republican party and Musk needs Trump's backing for federal autonomous vehicle regulations.
$1 Trillion Opportunity: The Wedbush tech analyst predicts that AI and autonomous vehicles will be a $1 trillion opportunity for Tesla and that the necessary regulatory initiatives will be fast-tracked by the Trump administration.&nbsp;
Though there will be some bumps in the road <a href="https://www.benzinga.com/markets/equities/25/06/45832827/elon-musks-father-says-trump-will-prevail-blames-sons-feud-mistake-on-stress-as-tesla-stock-slides-nearly-2-5-in-monday-pre-market">along the way</a>, Ives sees the potential for a $2 trillion Tesla market cap by the end of 2026.&nbsp;
"Rome was not built in a day," Ives said and maintained that Tesla "remains the most undervalued AI play in the market today."
Wedbush maintained Tesla shares with an Outperform rating and a $500 12-month price target.&nbsp;
TSLA Price Action: Tesla shares were down 0.13% at $294.75 at the time of publication Monday, according to <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>.&nbsp;
Read Next:&nbsp;
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/politics/25/06/45795080/whatever-you-think-of-elon-musk-you-must-support-his-fight-against-the-big-beautiful-bill-says-black-swan-author-nassim-taleb?utm_source=articleShare">&#8216;Whatever You Think Of Elon Musk, You Must Support His Fight Against The Big Beautiful Bill,&#8217; Says &#8216;Black Swan&#8217; Author Nassim Taleb</a>&nbsp;</li>
</ul>
Image: Shutterstock

Equities

Large Cap

TSLA

Tesla 'Remains The Most Undervalued AI Play': Dan Ives

Melius Research analyst Rob Wertheimer initiates coverage on Waste Management (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WM#NYSE">WM</a>) with a Buy rating and announces Price Target of $263.

Melius Research Initiates Coverage On Waste Management with Buy Rating, Announces Price Target of $263

NewAmsterdam Pharma Company N.V.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NAMS#NASDAQ">NAMS</a>) on Monday released topline data from pre-specified Alzheimer&#8217;s Disease biomarker analyses in the <a target="_blank" href="https://www.benzinga.com/pressreleases/25/06/g45832928/newamsterdam-pharma-announces-positive-topline-alzheimers-disease-data-from-broadway-clinical-tria" rel="noreferrer noopener">Phase 3 BROADWAY clinical trial</a>.
The study was primarily designed to evaluate the efficacy of obicetrapib in lowering low-density lipoprotein cholesterol (LDL-C) in adult patients with established atherosclerotic cardiovascular disease (ASCVD) and/or heterozygous familial hypercholesterolemia (HeFH), whose LDL-C is not adequately controlled despite being on maximally tolerated <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">lipid-lowering therapy</a>.
A pre-specified sub-study was conducted to assess the effect of obicetrapib on plasma biomarkers of Alzheimer&#8217;s in the full study population and patients carrying the ApoE4 gene.
Also Read: <a href="https://www.benzinga.com/general/biotech/24/12/42418025/why-is-newamsterdam-pharma-stock-trading-higher-on-tuesday" target="_blank" rel="noreferrer noopener">Why Is NewAmsterdam Pharma Stock Trading Higher On Tuesday?</a>
The company plans to present the full results from the AD sub-study analysis in a Developing Topics oral presentation at the Alzheimer&#8217;s Association International Conference in Toronto at the end of July 2025.
The primary endpoint was the LS mean percent change from baseline in LDL-C of obicetrapib 10 mg compared to placebo after 84 days, which showed a 33% reduction with imputation.
Secondary endpoints also included percent changes from baseline of obicetrapib 10 mg compared to placebo in ApoB, Lp(a), ApoA1, HDL-C, non-HDL-C, total cholesterol, and triglycerides at day 84, and on LDL-C levels at days 180 and 365.
Other exploratory outcome measures included time from randomization until the first confirmed occurrence of MACE in the obicetrapib arm compared to the placebo.
The trial also evaluated the safety and tolerability profile of obicetrapib.
In a note to investors, the investment firm William Blair expressed continued confidence in NewAmsterdam Pharma&#8217;s drug, obicetrapib, following the release of new clinical trial data.
William Blair analyst Matt Phipps said, &#8220;We continue to believe obicetrapib will offer a differentiated product profile in the marketplace, and while we have not factored in Alzheimer's benefit to our current assumptions, this could clearly provide significant long-term upside&#8230;we continue to believe seeing LDL reductions below 55% would be a positive for NewAmsterdam, particularly utilization of the fixed-dose-combination with ezetimibe.&#8221;
William Blair <a href="https://www.benzinga.com/quote/NAMS/analyst-ratings" target="_blank" rel="noreferrer noopener">maintained an Outperform rating</a> on NewAmsterdam Pharma, citing a 90% probability of success for obicetrapib. The analyst has derived a fair value for NewAmsterdam shares of $43.
Phipps asserted that obicetrapib could achieve a significant and clinically meaningful reduction in cardiovascular outcomes in the ongoing Phase 3 PREVAIL trial, potentially achieving a 20% or greater relative risk reduction.
Price Action: NAMS stock is trading lower by 1.04% to $19.93 at last check Monday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/general/biotech/25/05/45561443/sanofi-boosts-alzheimers-pipeline-with-vigil-neuroscience-acquisition" target="_blank" rel="noreferrer noopener">Sanofi Boosts Alzheimer&#8217;s Pipeline With Vigil Neuroscience Acquisition</a></li>
</ul>
Photo via Shutterstock

NAMS

Analyst Says NewAmsterdam Stock Has Over 100% Upside, Citing 90% Success Probability For Obicetrapib

Lake Street analyst Ben Klieve maintains American Vanguard (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AVD#NYSE">AVD</a>) with a Buy and lowers the price target from $14 to $12.

Lake Street Maintains Buy on American Vanguard, Lowers Price Target to $12

Loop Capital analyst Ananda Baruah maintains Hewlett Packard (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HPE#NYSE">HPE</a>) with a Hold and raises the price target from $16 to $18.

Loop Capital Maintains Hold on Hewlett Packard, Raises Price Target to $18

Contracts

Press Releases

Vast and Mabanaft Award SM1 Engineering Contracts to Fichtner and bse Methanol, with Arup's Dr. Amy Philbrook as Project Manager

Vast and GGS Energy Partner to Bring CSP-Powered Green Methanol and SAF to the U.S.

Peraso Inc. (NASDAQ: PRSO) Volume Soars as SAF Tehnika Adopts Technology Across a $3.4B Market North America & Europe – More Stocks Inside!

Financing

Vast Receives $30M from Australian Renewable Energy Agency for Green Technology to Decarbonise Australia's Grid and Power Green Fuels Production

Vast Updates Shareholders at Annual General Meeting on Significant Progress Towards Delivering Continuous, Carbon Free Energy to the World

Vast Ready to Deliver First-of-its-Kind Clean Energy Solution with Final Prototyping Completed

Vast Renewables Limited Announces Operational and Financial Results for First Half of Fiscal 2025

Vast's Clean Energy Project Secures up to AUD180 Million from the Australian Renewable Energy Agency to Power South Australia's Grid and Green Fuels Production

Vast Secures AUD 700,000 Grant from Australia-Singapore Initiative for Decarbonising Shipping to Progress World-First South Australia Solar Fuels Project

Comments

Vast Renewables Ltd

Vast Renewables Ltd (VSTE) Opciones

No option chain data available. Please try again later

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL